Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas
Open Access
- 17 June 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (9) , 1721-1723
Abstract
The tumor suppressor gene CDKN2A encodes p16INK4a and p14ARF which regulate cell cycle progression, and is frequently deleted in cancer. Homozygous deletion (homdel) of CDKN2A has been incorporated as a Grade 4 defining criterion for IDH-mutant gliomas without 1p-/19q-codeletion (IDHmut-noncodel) in the WHO CNS5 classification.1 However, the prognostic value of hemizygous CDKN2A deletions (hemidel) is unclear. We assessed copy number variation profiles of initial (n = 1256) and recurrent (n = 494) IDHmut gliomas to evaluate the impact of CDKN2A hemidel on overall survival (OS) outcomes ( Figure 1).Keywords
Funding Information
- National Institutes of Health (R01CA237208, R21NS114873, R21CA256575, U2CCA252979, P30CA034196)
- Deutsche Forschungsgemeinschaft
- William Guy Forbeck Research Foundation
This publication has 8 references indexed in Scilit:
- Glioma progression is shaped by genetic evolution and microenvironment interactionsCell, 2022
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancerNature Genetics, 2021
- Mechanisms and therapeutic implications of hypermutation in gliomasNature, 2020
- Longitudinal molecular trajectories of diffuse glioma in adultsNature, 2019
- Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized GliomasClinical Cancer Research, 2019
- DNA methylation-based classification of central nervous system tumoursNature, 2018
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaCell, 2016